This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Industry-University Cooperation Foundation Hanyang University. Active years: 2025-2026.
Company Filing History:
Years Active: 2025-2026
Title: Da Seul Im: Innovator in FLT3 Inhibitory Activity
Introduction
Da Seul Im is a prominent inventor based in Ansan-si, South Korea. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that exhibit inhibitory activity against fms-like tyrosine kinase 3 (FLT3). With a total of 2 patents to his name, his work is paving the way for targeted treatments in oncology.
Latest Patents
Im's latest patents include two notable inventions. The first is a quinazoline derivative having FLT3 inhibitory activity. This invention relates to a novel quinazoline derivative that exhibits excellent inhibitory activity against FLT3, which is crucial for the prevention or treatment of acute myeloid leukemia (AML). The second patent is for an imidazole derivative expressing FLT3 inhibitory activity. This benzimidazole derivative also shows promising results in inhibiting FLT3, further supporting targeted treatment approaches for AML.
Career Highlights
Da Seul Im is affiliated with the Industry-University Cooperation Foundation at Hanyang University. His work in this institution has allowed him to collaborate with other researchers and contribute to advancements in cancer treatment.
Collaborations
Some of his notable coworkers include Jung-Mi Hah and Jung Mi Hah. Their collaborative efforts have been instrumental in the research and development of innovative therapeutic compounds.
Conclusion
Da Seul Im's contributions to the field of medicinal chemistry, particularly in developing FLT3 inhibitors, highlight his role as an influential inventor. His work promises to enhance treatment options for patients with acute myeloid leukemia.